Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma

References

• National Institutes of Health. National Cancer Institute. Nasopharyngeal cancer treatment (PDQ®)-health professional version; 2022 Jul 13. Available from: https://www.cancer.gov/types/head-and-neck/hp/adult/nasopharyngeal-treatment-pdq
   Google Scholar
• Argirion I, Zarins KR, Ruterbusch JJ, et al. Increasing incidence of Epstein-Barr Virus-related nasopharyngeal carcinoma in the United States. Cancer. 2020;126(1):121–130. doi: 10.1002/cncr.32517.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Ma S. Racial differences in nasopharyngeal carcinoma in the United States. Cancer Epidemiol. 2013;37(6):1–15.
   PubMed Web of Science ®Google Scholar
• Nam J, McLaughlin JK, Blot WJ. Cigarette smoking, alcohol, and nasopharyngeal carcinoma: a case-control study among US whites. J Natl Cancer Inst. 1992;84(8):619–622. doi: 10.1093/jnci/84.8.619.
   PubMedGoogle Scholar
• Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev. 1996;5(8):587–593.
   PubMed Web of Science ®Google Scholar
• Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961–1970. doi: 10.1001/jama.2023.20181.
   PubMed Web of Science ®Google Scholar
• Hsu C, Lee S-H, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 Study. J Clin Oncol. 2017;35(36):4050–4056. doi: 10.1200/JCO.2017.73.3675.
   PubMed Web of Science ®Google Scholar
• Chan ATC, Lee VHF, Hong R-L, et al. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol. 2023;34(3):251–261. doi: 10.1016/j.annonc.2022.12.007.
   PubMed Web of Science ®Google Scholar
• Keytruda® (pembrolizumab) Prescribing Information. Merck & Co., Inc. Whitehouse Station, NJ; 2023 Dec. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Head and neck cancers Version 3.2024. 2024 Feb 29. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437
   Google Scholar
• Bossi P, Chan AT, Even C, et al. ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease. Ann Oncol. 2023;34(3):247–250. doi: 10.1016/j.annonc.2022.11.011.
   PubMed Web of Science ®Google Scholar
• Keytruda® (pembrolizumab) cost info & financial help. Merck & Co., Inc., Rahway, NJ; 2023 Sep. Available from: https://www.keytruda.com/financial-support/
   Google Scholar
• United States Securities and Exchange Commission Form 8-K. Coherus Biosciences, Inc; 2023 Nov 27. Available from: https://investors.coherus.com/node/12656/html
   Google Scholar
• Abraham I, Calamia M, Pondel M, et al. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. J Med Econ. (under review).
   Google Scholar
• MacDonald K, Calamia M, Pondel M, et al. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in locally advanced or metastatic nonsquamous non-small cell lung cancer. J Med Econ. (in preparation).
   Google Scholar
• Abraham I, Calamia M, Pondel M, et al. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in locally advanced or metastatic nonsquamous non-small cell lung cancer. J Med Econ. (in preparation).
   Google Scholar
• MacDonald K, Calamia M, Pondel M, et al. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in esophageal squamous cell carcinoma. J Med Econ. (in preparation).
   Google Scholar
• Abraham I, Calamia M, Pondel M, et al. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab esophageal squamous cell carcinoma. J Med Econ. (in preparation).
   Google Scholar
• Abraham I, Calamia M, Pondel M, et al. Efficiencies, opportunity and affordability: economic evaluations of the novel PD-1 inhibitor toripalimab versus pembrolizumab. J Med Econ. (in preparation).
   Google Scholar
• MacDonald K, McBride A, Alrawashdh N, et al. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. J Med Econ. 2020;23(12):1466–1476. doi: 10.1080/13696998.2020.1833339.
   PubMed Web of Science ®Google Scholar
• McBride A, MacDonald K, Abraham I. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. Leuk Res. 2021;106:106591. doi: 10.1016/j.leukres.2021.106591.
   PubMed Web of Science ®Google Scholar
• MacDonald K, Alrawashdh N, McBride A, et al. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncol. 2021;17(33):4561–4570. doi: 10.2217/fon-2021-0718.
   PubMed Web of Science ®Google Scholar
• McBride A, Alrawashdh N, MacDonald K, et al. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncol. 2022;18(3):363–373. doi: 10.2217/fon-2021-0979.
   PubMed Web of Science ®Google Scholar
• Worldometer. United States population. 2020 yearly population growth rate. 2020. Available from: https://www.worldometers.info/world-population/us-population/
   Google Scholar
• Merative. Merative Micromedex® Red Book® 2023. Ann Arbor, MI. 2023. Available from: www.micromedexsolutions.com
   Google Scholar
• Centers for Medicare and Medicaid Services. 2024 ASP drug pricing files: January 2024 ASP Pricing file. 2024. Available from: https://www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files
   Google Scholar
• Centers for Medicare and Medicaid Services. Medicare hospital outpatient PPS Addendum B update. 2024 Jan. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates
   Google Scholar
• De Felice F, Tombolini V, de Vincentiis M, et al. Multidisciplinary team in head and neck cancer: a management model. Med Oncol. 2019;36(1):2. doi: 10.1007/s12032-018-1227-z.
   Web of Science ®Google Scholar